Clinical benefit of baricitinib treatment for moderate-to-severe atopic dermatitis in combination with topical corticosteroids: a post hoc analysis of the BREEZE-AD7 and BREEZE-AD4 phase III trials

BRITISH JOURNAL OF DERMATOLOGY

WILEY

1. Eli Lilly and Company